Abivax sa - adr ABVX.US 總覽分析
ABVX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ABVX 近期報酬表現
4.05%
Abivax sa - adr
3.56%
同產業平均
1.47%
S&P500
與 ABVX 同產業的標的表現
- BCAX Bicara therapeutics inc價值 -趨勢 3 分波段 4 分籌碼 3 分股利 1 分查看更多
ABVX 公司資訊
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.